VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...

An expert discusses how his diagnostic treatment workflow for a new patient with benign prostatic hyperplasia (BPH) progresses from initial α-blocker therapy through noninvasive systematic testing ...

CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir. Phase 3 data from the PrTK03 trial (NCT01436968) were recently presented at the ...

The BiPASS trial explores combining MRI and PSMA-PET imaging to enhance prostate cancer diagnostic accuracy and reduce biopsy necessity. Illuccix and Gozellix are currently approved for specific ...

The Signatera ctDNA test predicts which MIBC patients benefit from adjuvant atezolizumab, showing significant DFS and OS improvements in MRD-positive patients. The IMvigor011 trial enrolled 760 ...

Badalato is vice chair of Education & Faculty Affairs and an associate professor of urology at Columbia University Irving Medical Center in New York, New York. "Osteopathic urologists were more likely ...

Prostate cancer awareness is crucial year-round, emphasizing screening and meaningful conversations about risk and prevention. Screening guidelines vary, focusing on shared decision-making and ...

Darolutamide showed modest efficacy in mCRPC patients post-ARPI treatment, with varying clinical benefit rates across molecularly defined cohorts. Higher clinical benefit rates were observed in ...

“What [we] found was that those men who received a penile implant had a significant reduction in depression and psychological distress," says Mohit Khera, MD, MBA, MPH. Implantable penile prosthesis ...

The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant radiographic ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

The proposed budget cut reduces CDMRP funding from $1.509 billion in FY2024 to $650 million in FY2025, affecting cancer research funding. Organizations like Zero Prostate Cancer and the American ...